Elicio Therapeutics, Inc. presented updated results from its Phase 1 AMPLIFY-201 clinical trial of ELI-002 at the ESMO Immuno-Oncology Congress 2024 on December 12, 2024. The data, with a median study follow-up of 19.7 months, included a median recurrence-free survival (mRFS) of 16.3 months and a median overall survival (mOS) of 28.9 months for the full study population.
The AMPLIFY-201 trial evaluated ELI-002 in 25 individuals with mKRAS-driven colorectal or pancreatic cancer who remained at high risk of disease recurrence after standard treatment. ELI-002 continued to demonstrate a favorable safety profile and elicited mKRAS-specific T cell responses in most patients.
A strong correlation was observed between mRFS and the strength of the T cell response, reinforcing the mechanism of action and potential clinical benefit of ELI-002. These updated results build upon earlier data published in Nature Medicine and support the ongoing development of the ELI-002 7P formulation in the Phase 2 AMPLIFY-7P trial, with an interim analysis expected in the first half of 2025.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.